NASDAQ:MLNT - Melinta Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.02 +0.04 (+4.08 %) (As of 01/18/2019 04:00 PM ET)Previous Close$1.02Today's Range$0.98 - $1.0452-Week Range$0.64 - $15.25Volume462,406 shsAverage Volume755,303 shsMarket Capitalization$54.96 millionP/E Ratio-0.05Dividend YieldN/ABeta2.13 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP. The company also develops Baxdela that in a Phase III clinical trial for treating community-acquired bacterial pneumonia (CABP)); Fusidic Acid, which is in Phase III clinical trial for treating ABSSSIs; and radezolid, a melinta molecule that is in Phase II clinical trial for dermatological applications, as well as ESKAPE pathogen program, which is in preclinical stage targeting superbugs. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals, Inc. and changed its name to Melinta Therapeutics, Inc. in October 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut. Receive MLNT News and Ratings via Email Sign-up to receive the latest news and ratings for MLNT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:MLNT Previous Symbol CUSIP15130J10 Webmelinta.com Phone908-617-1309Debt Debt-to-Equity Ratio0.46 Current Ratio1.34 Quick Ratio1.04Price-To-Earnings Trailing P/E Ratio-0.05 Forward P/E Ratio-0.28 P/E GrowthN/A Sales & Book Value Annual Sales$33.86 million Price / Sales1.69 Cash FlowN/A Price / Cash FlowN/A Book Value$2.31 per share Price / Book0.44Profitability EPS (Most Recent Fiscal Year)($21.86) Net Income$-58,910,000.00 Net Margins-202.31% Return on Equity-68.68% Return on Assets-32.84%Miscellaneous Employees300 Outstanding Shares56,020,000Market Cap$54.96 million OptionableOptionable Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions What is Melinta Therapeutics' stock symbol? Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT." How were Melinta Therapeutics' earnings last quarter? Melinta Therapeutics Inc (NASDAQ:MLNT) posted its earnings results on Wednesday, November, 7th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.05) by $0.55. The biotechnology company had revenue of $34.08 million for the quarter, compared to analysts' expectations of $17.24 million. Melinta Therapeutics had a negative net margin of 202.31% and a negative return on equity of 68.68%. View Melinta Therapeutics' Earnings History. When is Melinta Therapeutics' next earnings date? Melinta Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Melinta Therapeutics. What price target have analysts set for MLNT? 7 equities research analysts have issued 1 year target prices for Melinta Therapeutics' shares. Their forecasts range from $8.00 to $15.00. On average, they expect Melinta Therapeutics' share price to reach $12.5833 in the next twelve months. This suggests a possible upside of 1,133.7% from the stock's current price. View Analyst Price Targets for Melinta Therapeutics. What is the consensus analysts' recommendation for Melinta Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Melinta Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Melinta Therapeutics. What are Wall Street analysts saying about Melinta Therapeutics stock? Here are some recent quotes from research analysts about Melinta Therapeutics stock: 1. According to Zacks Investment Research, "Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products that were developed internally or assumed under the 2017 acquisition of Cempra, Inc. This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Melinta is headquartered in New Haven, CT. " (1/17/2019) 2. LADENBURG THALM/SH SH analysts commented, "We are transferring coverage of Melinta Therapeutics, maintaining our Buy rating and $14.00 price target. Melinta is an antibiotics company with four marketed products in the for acute bacterial skin and skin structure infections (ABSSSI), Vabomere for complicated urinary tract infections and Minocin IV for several serious infections (see pages 2-3 for details). Additional candidates are also in development for several indications (see Exhibit 1). With scaled back launch expectations, we believe Vabomere and Baxdela (launched January 2018, respectively) can reach more modest consensus estimates and represents an attractive value currently." (12/18/2018) 3. HC Wainwright analysts commented, "We note that Orbactiv is already approved by the EMA, whereas a MAA has yet to be filed for Minocin. While we await an 8-K filing for more details on the financial terms of this agreement, we point to three more near-term milestones for MLNT: (1) seven posters and one oral presentation later this week at Francisco (we are in attendance for the full duration); (2) sales and prescription trends from the 3Q18 results expected in early the pivotal Phase 3 data for Baxdela in community-acquired bacterial pneumonia (CABP) before year end. Affirm Buy." (10/2/2018) Has Melinta Therapeutics been receiving favorable news coverage? Headlines about MLNT stock have been trending somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Melinta Therapeutics earned a news impact score of 1.7 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. Are investors shorting Melinta Therapeutics? Melinta Therapeutics saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 1,670,986 shares, a decrease of 50.2% from the December 14th total of 3,356,900 shares. Based on an average daily trading volume, of 1,166,565 shares, the short-interest ratio is currently 1.4 days. Currently, 4.6% of the company's shares are sold short. View Melinta Therapeutics' Current Options Chain. Who are some of Melinta Therapeutics' key competitors? Some companies that are related to Melinta Therapeutics include Arbutus Biopharma (ABUS), Aeglea Bio Therapeutics (AGLE), Kamada (KMDA), XBiotech (XBIT), Paratek Pharmaceuticals (PRTK), LifeVantage (LFVN), Geron (GERN), Cerecor (CERC), Aratana Therapeutics (PETX), Athersys (ATHX), MEI Pharma (MEIP), Xenon Pharmaceuticals (XENE), Newron Pharmaceuticals (NWPHF), Kala Pharmaceuticals (KALA) and Galectin Therapeutics (GALT). Who are Melinta Therapeutics' key executives? Melinta Therapeutics' management team includes the folowing people: Dr. Erin M. Duffy Ph.d., Chief Scientific Officer (Age 51)Mr. John H. Johnson, CEO & Director (Age 61)Dr. Thomas A. Steitz Ph.D., Co-FounderDr. Peter B. Moore Ph.D., Co-FounderDr. William L. Jorgensen Ph.D., Co-Founder How do I buy shares of Melinta Therapeutics? Shares of MLNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Melinta Therapeutics' stock price today? One share of MLNT stock can currently be purchased for approximately $1.02. How big of a company is Melinta Therapeutics? Melinta Therapeutics has a market capitalization of $54.96 million and generates $33.86 million in revenue each year. The biotechnology company earns $-58,910,000.00 in net income (profit) each year or ($21.86) on an earnings per share basis. Melinta Therapeutics employs 300 workers across the globe. What is Melinta Therapeutics' official website? The official website for Melinta Therapeutics is http://melinta.com. How can I contact Melinta Therapeutics? Melinta Therapeutics' mailing address is 300 GEORGE STREET SUITE 301, NEW HAVEN CT, 06511. The biotechnology company can be reached via phone at 908-617-1309 or via email at [email protected] MarketBeat Community Rating for Melinta Therapeutics (NASDAQ MLNT)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 507 (Vote Outperform)Underperform Votes: 372 (Vote Underperform)Total Votes: 879MarketBeat's community ratings are surveys of what our community members think about Melinta Therapeutics and other stocks. Vote "Outperform" if you believe MLNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLNT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/19/2019 by MarketBeat.com StaffFeatured Article: What is the Current Ratio?